No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...

Autophagy is the process by which cells digest and renew their internal structures, recycling damaged or malfunctioning ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Headed by Drs. Antonio Zorzano and Saska Ivanova, a study published in the journal Autophagy unravels the relationship between mitofusins (mitochondrial proteins) and autophagy. Using gene editing ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

The Food and Drug Administration approval in December 2023 of the first CRISPR therapeutic, Casgevy to treat sickle cell, came 11 years after the discovery of the revolutionary gene-editing technology ...